NEUROLOGY
Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson’s disease
Figure 24.1 Phases of development for a surrogate marker of progression in Parkinson’s disease (PD). Biomarker discovery leads to identification of species that are most often first studied in cross-sectional…
Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson’s disease
Figure 19.1 Deep-brain stimulation selection decision-making algorithm, based on CAPSIT criteria. Reproduced with permission from Duker AP, Espay AJ. Surgical Treatment of Parkinson Disease: Past, Present, and Future. Neurol Clin…
Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson’s disease
Figure 6.1 Structure of dopamine and rotigotine. Pharmacokinetics Rotigotine has a broad spectrum of action across the D1–D5 receptors (Table 6.3) [12]. This, particularly its D1 activity, is in theory…
Management of pain and neuromuscular complications in Parkinson’s disease
Figure 16.1 Central pain pathways in Parkinson’s disease. Left: The lateral system is formed by the neospinothalamic, the neotrigeminothalamic, the cervical bundle and the beam of the dorsal horn whose…
